Abstract
Around ten years ago, the first evidence that targeting microtubule system could be a potential strategy in slowing down neurodegeneration was reported. Several teams have been working to better shape this idea and the scientific community has now the opportunity of fishing into a large amount of data coming from in vitro and in in vivo studies. Notably, these results have driven clinical trials addressing tauopathies. Unfortunately, moving such a neuroprotective strategy from mice to men has revealed unexpected concerns and results that do not fit with the promising background. Here we aim to focus the rationale for the design of a microtubule-based therapy in neurodegeneration, look at the results achieved and discuss the future perspectives.
Keywords: Microtubule, neurodegeneration, neuroprotection, therapy.
Current Pharmaceutical Design
Title:Microtubule-Directed Therapeutic Strategy for Neurodegenerative Disorders: Starting From the Basis and Looking on the Emergences
Volume: 23 Issue: 5
Author(s): Graziella Cappelletti, Daniele Cartelli, Michael S. Christodoulou and Daniele Passarella
Affiliation:
Keywords: Microtubule, neurodegeneration, neuroprotection, therapy.
Abstract: Around ten years ago, the first evidence that targeting microtubule system could be a potential strategy in slowing down neurodegeneration was reported. Several teams have been working to better shape this idea and the scientific community has now the opportunity of fishing into a large amount of data coming from in vitro and in in vivo studies. Notably, these results have driven clinical trials addressing tauopathies. Unfortunately, moving such a neuroprotective strategy from mice to men has revealed unexpected concerns and results that do not fit with the promising background. Here we aim to focus the rationale for the design of a microtubule-based therapy in neurodegeneration, look at the results achieved and discuss the future perspectives.
Export Options
About this article
Cite this article as:
Cappelletti Graziella, Cartelli Daniele, Christodoulou S. Michael and Passarella Daniele, Microtubule-Directed Therapeutic Strategy for Neurodegenerative Disorders: Starting From the Basis and Looking on the Emergences, Current Pharmaceutical Design 2017; 23 (5) . https://dx.doi.org/10.2174/1381612822666161214150544
DOI https://dx.doi.org/10.2174/1381612822666161214150544 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuropeptides in Alzheimer’s Disease: An Update
Current Alzheimer Research The Blood-Brain Barrier in NeuroAIDS
Current HIV Research Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating
Current Medicinal Chemistry Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Oxidative Stress and Neurodegenerative Diseases: A Neurotrophic Approach
Current Drug Targets Drugs and Foods for Chronic Subclinical Inflammation in Humans
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Comparison of Various Types of Ligand Decorated Nanoliposomes for their Ability to Inhibit Amyloid Aggregation and to Reverse Amyloid Cytotoxicity
Current Topics in Medicinal Chemistry New Anti-Alzheimer Drugs from Biodiversity: The Role of the Natural Acetylcholinesterase Inhibitors
Mini-Reviews in Medicinal Chemistry Pharmacophore, Similarity and ADMET Screening of Casein Kinase 1 inhibitors in Alzheimer's Disease
Current Bioactive Compounds Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Editorial: New Avenues and Therapeutic Strategies for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
Current Pharmaceutical Design The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Development of a Novel and Robust Pharmacological Model of Okadaic Acid-induced Alzheimer’s Disease in Zebrafish
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer’s Disease
Current Pharmaceutical Design